Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
KR20200132899A
How to treat cancer in pediatric patients
CN110520110A
Pharmaceutical preparation comprising the chloro- N4- of 5- [2- (solutions of dimethyl phosphoryl base) phenyl]-N2- { 2- methoxyl group -4- [4- (4- methylpiperazine-1-yl) piperidin-1-yl] phenyl } pyrimidine -2,4- diamines
CA3047107A1
Benzimidazole compounds as c-kit inhibitors
WO2018112136A1
Aminothiazole compounds as c-kit inhibitors
WO2018102366A1
Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
WO2018081531A2
Methods for human t-cell activation
WO2018071809A1
Inducible t-cell system and uses thereof
WO2016183278A1
Heteroaryl compounds for kinase inhibition
CN107108559A
5 chlorine N4 [2 (solutions of dimethyl phosphoryl base) phenyl] N2 { crystalline forms of the diamines of 2 methoxyl group 4 [4 (base of 4 methyl piperazine 1) piperidinyl-1 base] pyrimidine 2,4
AU2015210454A1
Bicyclic heteroaryl compounds
CN106687457A
Heteroaryl compounds for kinase inhibition
CR20170011A
HETEROARILO COMPOUNDS FOR INHIBITION OF CINASA
US2014349968A1
Compositions and Methods for Treating Cancer
US9611283B1
Methods for inhibiting cell proliferation in ALK-driven cancers
EP2968358A1
Novel choline kinase inhibitors
CA2815506A1
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2013204506A1
Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
